Effectiveness of phenytoin-caffeine combination in general seizure

Effectiveness of phenytoin-caffeine combination in general seizure - The study of phenytoin-caffeine combination in general seizure

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012255

Enrollment

Registered

2013-12-20

Start date

2012-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy with general seizure

Interventions

Patients receive phenytoin 5mg/kg Patients receive phenytoin 5mg/kg-caffeine 2.5mg/kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: General seizure

Exclusion criteria

Exclusion criteria: Diabetes Mellitus, acute or chronic myocard infarction, hypertension, chronic liver diseases

Design outcomes

Primary

Measure	Time frame
Seizure frequency, seizure reduction>50%, 6 month remission	—

Secondary

Measure	Time frame
Plasma phenytoin concentration, and adverse drug reaction.	—

Countries

Asia(except Japan)

Contacts

Public ContactDr. Widyati, MClin Pharm

dr. Ramelan Navy Hospital Pharmacy department

widyatiw@yahoo.com6231081331383111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026